• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Guaranteed Paid Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Una encuesta epidemiológica sobre enfermedad venosa crónica muestra la importancia del tratamiento temprano


News provided by

Servier

Sep 14, 2011, 03:00 ET

Share this article

Share this article


PRAGA, September 14, 2011 /PRNewswire/ --

 

- La mayor encuesta epidemiológica sobre enfermedad venosa crónica a 70.000 pacientes muestra la importancia del tratamiento temprano  

- "El diagnóstico y tratamiento temprano de la enfermedad venosa crónica (EVC) son obligatorios para prevenir la progresión a fases clínicas más severas, incluyendo las úlceras venosas"

El Programa VEIN CONSULT, la mayor encuesta epidemiológica sobre enfermedad venosa crónica desarrollada bajo los auspicios de la International Union of Phlebology (UIP) y apoyada por una beca no restringida del Servier Research Group, es un esfuerzo educativo internacional para elevar la concienciación sobre la EVC entre pacientes, científicos y autoridades sanitarias. Es la primera encuesta en monitorizar un gran número de pacientes de muchos países de varias áreas geográficas (Europa, Oriente Medio, Lejano Oriente, América central y Latinoamérica) utilizando el mismo cuestionario y la misma clasificación (clasificación CEAP).

Los primeros resultados del Programa VEIN CONSULT muestran que la enfermedad venosa crónica tiene un importante impacto negativo en las vida profesional de los pacientes, resultando en grandes pérdidas de productividad; el 15% de los pacientes con enfermedad venosa crónica notifican pérdidas de días de trabajo. La EVC es también responsable de sufrimiento físico y psicológico de los pacientes, que se refleja en una peor calidad de vida. Observamos un importante deterioro en la calidad de vida al aumentar la gravedad de la enfermedad. Esto afecta directamente a los costes relacionados con la EVC, casi un 4% de los pacientes han tenido que cambiar de empleo por su enfermedad venosa y más del 6% han tenido que ser hospitalizados.  

Por primera vez se ha tenido en cuenta a los pacientes únicamente sintomáticos y la EVC se ha considerado desde las primeras fases, con el objetivo de mejorar el proceso de tratamiento.

 Ocho de cada 10 pacientes sufren enfermedad venosa crónica, desde dolor venoso hasta las fases más avanzadas como edema y úlcera. Gracias al Programa VEIN CONSULT, podemos evaluar por primera vez la prevalencia de pacientes con EVC con solo síntomas (dolor de piernas, pesadez, sensación de hinchazón…). Los primeros resultados de varios países muestran que el 20% de los participantes se clasifican como pacientes con únicamente síntomas, mientras que el 61,2% se clasifican como pacientes con signos visibles de enfermedad venosa crónica (varicosidades, venas varicosas, edema, y úlcera).

Los pacientes no consultan espontáneamente el dolor en las piernas y los médicos no consideran el dolor venoso como parte de la enfermedad. A pesar del impacto de la enfermedad venosa crónica en los costes y calidad de vida, muchos de los pacientes de enfermedad venosa crónica todavía están sin diagnosticar y sin tratar.

"La progresión a fases clínicas más tardías debido a un retraso en el inicio del tratamiento puede llevar a la pérdida de días laborables, menor calidad de vida y mayores costes globales", dijo el profesor Rabe, actual presidente de la International Union of Phlebology.

El Programa VEIN CONSULT continuará activo hasta 2012 en más de 20 países. Los resultados de los primeros 70.000 pacientes monitorizados en 13 países (Brasil, Francia, Georgia, Hungría, México, Pakistán, Rumania, Rusia, Serbia, Singapur, Eslovaquia, España, y Emiratos Árabes Unidos) se presentaron durante una sesión totalmente dedicada a él durante el congreso de la UIP en Praga.

El Comité científico de UIP

Notas al redactor:

Acerca de la International Union of Phlebology (UIP)

La International Union of Phlebology es una organización internacional cuyo objetivo es avanzar en la excelencia e innovación en enfermedades venosas y linfáticas mediante la educación, defensa e investigación.

El Programa VEIN CONSULT se realiza bajo los auspicios de la UIP y está apoyado por una beca educativa no restringida del Servier Research Group.

Referencias:

Rabe E. Update on the Vein Consult Program: the world's largest awareness programme in chronic venous disease. Abstract published as a supplement in Practical Phlebology, European chapter meeting of the UIP, Prague, Czech Republic, 14-17th September 2011.

Puskas A. First results from the 70 000 patients screened in primary health care in the Vein Consult Program. Abstract published as a supplement in Practical Phlebology, European chapter meeting of the UIP, Prague, Czech Republic, 14-17th September 2011.

Mansilha A. Quality of life and costs of chronic venous disease: first results from the Vein Consult Program. Abstract published as a supplement in Practical Phlebology, European chapter meeting of the UIP, Prague, Czech Republic, 14-17th September 2011.

Fernandez Quesada F. First results from the patients followed up by specialists in the Vein Consult Program. Abstract published as a supplement in Practical Phlebology, European chapter meeting of the UIP, Prague, Czech Republic, 14-17th September 2011.

SOURCE Servier

Modal title

Also from this source

Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio

Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio


Servier et QIAGEN signent un partenariat pour développer un nouveau test diagnostique compagnon de détection des mutations IDH1 pour soutenir le développement du portefeuille de Servier en onco-hématologie

Servier et QIAGEN signent un partenariat pour développer un nouveau test diagnostique compagnon de détection des mutations IDH1 pour soutenir le développement du portefeuille de Servier en onco-hématologie

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Medical Equipment
  • Surveys, Polls and Research

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.